Daphne Koller: Machine learning and multimodal data in drug discovery

“We are now in a world where there is this an abundance of data,
which is only the beginning to what we're likely to be able to
see in the coming years. At the same time, we have this
incredible set of machine learning methods [...]. This seems to
be a moment in time when those two tidal waves are about to come
together in a way that offers us the opportunity to unlock some
of the underlying secrets and complexities that underlie human
health and human disease.”


This week we are sharing for posterity the discussion that Parker
Moss, our Chief Commercial Officer, hosted earlier this month at
the Genomics England Research Summit. Parker’s discussion was
with the world renowned Daphne Koller, the founder and CEO of
insitro.


Parker and Daphne explored the use of AI and machine learning in
drug discovery and discussed the value of multimodal analysis.
They also touched on some of the challenges of causal inference
and target validation with unsupervised machine learning
methodologies. Parker and Daphne then discussed the recent
partnership between Genomics England and insitro.